Cancer based pharmacogenomics network supported with scientific evidences: From the view of drug repurposing

Liwei Wang, Hongfang Liu, Christopher G. Chute, Qian Zhu

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient's genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment. Methods: In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies. Conclusions: The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.

Original languageEnglish (US)
Article number042
JournalBioData Mining
Issue number1
StatePublished - Jan 8 2015


  • Cancer
  • Drug repurposing
  • Network
  • Pharmacogenomics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Computer Science Applications
  • Computational Theory and Mathematics
  • Computational Mathematics


Dive into the research topics of 'Cancer based pharmacogenomics network supported with scientific evidences: From the view of drug repurposing'. Together they form a unique fingerprint.

Cite this